Valbiotis SA (ALVAL.PA)

6.14 €

-0.12 (-1.92%)
Rating:
Recommendation:
-
Symbol ALVAL.PA
Price 6.14 €
Beta 0.637
Volume Avg. 0.01M
Market Cap 60.846M
Shares () -
52 Week Range 4.01-7.45
1y Target Est -
DCF Unlevered ALVAL.PA DCF ->
DCF Levered ALVAL.PA LDCF ->
ROE -47.12% Strong Sell
ROA -18.81% Sell
Operating Margin -
Debt / Equity 99.66% Buy
P/E -
P/B 2.02 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Mr. Sbastien Peltier
Healthcare
Biotechnology
Paris

Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.